Iovance Biotherapeutics, Inc.
8.43USD
-0.2700 (-3.10%)
Fetching financial statements from SEC filings…
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 99 | 71 | 87 | 67 | 60 | 49 | 74 | 59 |
| Cost of Revenue | 44 | 42 | 43 | 38 | 49 | 43 | 38 | 32 |
| Gross Profit | 56 | 29 | 44 | 29 | 11 | 7 | 36 | 27 |
| Operating Income | -52 | -81 | -73 | -95 | -114 | -121 | -87 | -89 |
| Net Income | -47 | -79 | -72 | -91 | -112 | -116 | -79 | -84 |
| EPS (Diluted) | $-0.11 | $-0.19 | — | — | $-0.33 | $-0.36 | $-0.25 | $-0.28 |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)